- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04551482
Oxytocin for Weight Loss in Adolescents
Oxytocin as a Neuroendocrine Therapy for Obesity in Youth
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In recent years there has been a dramatic increase in obesity and its complications in both children and adults. Earlier treatment substantially reduces the likelihood of developing complications later in life while concurrently improving quality of life and decreasing mortality. Therefore, it is essential to develop safe and effective therapeutic strategies for weight loss, particularly in adolescents. Oxytocin (OXT), a hypothalamic peptide hormone that regulates energy balance, is a novel neuroendocrine weight-loss therapeutic in adults with obesity because it simultaneously reduces energy intake and increases energy expenditure and is well-tolerated. Data are currently lacking regarding effects of OXT administration in adolescents with obesity.
The current study is a 12-week randomized controlled trial (RCT) of OXT vs. placebo in 12-18-year old adolescents with obesity. We hypothesize that OXT administration will decrease weight as a consequence of decreased caloric intake and increased energy expenditure, both partially mediated by reduced hypothalamic inflammation (such inflammation drives weight gain by increasing food intake and reducing energy expenditure). Further, OXT will improve metabolic risk markers, such as visceral and intrahepatic fat, systemic inflammation, and serum lipids.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Elizabeth A Lawson, MD, MMSc
- Phone Number: 617-726-3870
- Email: ealawson@partners.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Elizabeth A Lawson, MD
- Email: ealawson@partners.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and Females, 12-18 years
- Obesity (BMI ≥95th percentile for age and gender)
- Willingness to maintain current diet and lifestyle for the duration of study participation
Exclusion Criteria:
- Active substance abuse
- Use of prescription or over-the-counter drugs or dietary/herbal supplements for the purpose of weight loss. Medications/supplements that may affect weight will be allowed if participants are on a stable dose with stable weight for at least 3 months.
- Greater than 5kg weight loss over 3 months;
- Follows a nonstandard diet (e.g., gluten-free, vegan, Paleo, Atkins, raw diet, macrobiotic diet)
- Cardiovascular disease
- Prolonged QT interval
- Chronic gastrointestinal disorders and other inflammatory conditions
- Epilepsy
- Untreated thyroid disease
- Alanine transaminase (ALT) or aspartate transaminase (AST) >2.5 times upper limit of normal
- Creatinine >1.5 mg/dl
- Hyponatremia
- Pregnancy/breastfeeding or refusal to use contraception not containing estrogen throughout the study if female and sexually active
- MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clips
- Weight >450 lbs due to limits for MRI and DXA scanners
- Type 1 DM or type 2 Diabetes Mellitus if HbA1c >8%
- Active eating disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oxytocin
Oxytocin nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
|
24 IU nasal spray, 4 times per day for 12 weeks
Other Names:
|
Placebo Comparator: Placebo
Placebo nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
|
24 IU nasal spray, 4 times per day for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight
Time Frame: 12 weeks
|
Mean difference in weight between Oxytocin and Placebo group after 12 weeks of treatment
|
12 weeks
|
Height
Time Frame: Baseline
|
Measure height on a stadiometer to the nearest 0.1 cm
|
Baseline
|
Body mass index (BMI)
Time Frame: 12 weeks
|
Mean difference in BMI between Oxytocin and Placebo group after 12 weeks of treatment.
BMI will be calculated as weight/height2
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lean mass and Fat mass
Time Frame: 12 weeks
|
Dual Energy Absorptiometry (DXA) will be used for measuring fat mass (kg) and lean mass (Kg)
|
12 weeks
|
Fasting Resting Energy Expenditure (kCal)
Time Frame: 12 weeks
|
Assessed by Indirect calorimetry
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth Lawson, MD, MMSc, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020P002511
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity, Adolescent
-
National University of MalaysiaUniversiti Putra Malaysia; University of RoehamptonCompletedAdolescent Obesity | Adolescent Behavior | Adolescent OverweightMalaysia
-
University of OxfordOxford Brookes UniversityRecruitingOverweight/Obesity, AdolescentUnited Kingdom
-
VIVUS LLCCompletedAdolescent Obesity | Obesity in Adolescence | Adolescent OverweightUnited States
-
Delta University for Science and TechnologyCompletedObesity, Adolescent | Adolescent DevelopmentEgypt
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity, Adolescent | Adolescent Behavior
-
Children's Hospital of PhiladelphiaNational Institutes of Health (NIH)Not yet recruitingAdolescent Obesity | Diet, Healthy | Adolescent Overweight
-
University of BedfordshireCompletedInsulin Resistance | Adolescent Obesity | Adolescent BehaviorUnited Kingdom
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Guangzhou Sport UniversityUnknownChildhood Obesity | Adolescent ObesityChina
Clinical Trials on Oxytocin nasal spray
-
Sara EspinozaThe University of Texas Health Science Center, Houston; The University of Texas... and other collaboratorsCompletedObesity | Sedentary Lifestyle | Sarcopenia | Aging | Sarcopenic ObesityUnited States
-
University Hospital, ToulouseCompletedPrader-Willi SyndromeFrance
-
University of Electronic Science and Technology...Completed
-
Massachusetts General HospitalCompleted
-
University of Sao Paulo General HospitalTerminated
-
Rambam Health Care CampusCompletedPost Traumatic Stress DisorderIsrael
-
Florida Institute for Human and Machine CognitionUniversity of Alabama at Birmingham; University of Florida; Translational Genomics... and other collaboratorsCompleted
-
Florida Institute for Human and Machine CognitionUniversity of Florida; Office of Naval Research (ONR)Completed
-
University of North Carolina, Chapel HillCompletedSchizophrenia | Schizoaffective Disorder | ParanoiaUnited States
-
Stanford UniversityCompleted